PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2013 | 8 | 6 | 835-844
Tytuł artykułu

Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Wydawca
Czasopismo
Rocznik
Tom
8
Numer
6
Strony
835-844
Opis fizyczny
Daty
wydano
2013-12-01
online
2013-12-06
Twórcy
autor
  • Hematology Unit, Azienda Ospedaliera ‘Bianchi-Melacrino-Morelli’, Reggio Calabria, Italy
Bibliografia
  • [1] Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189–199
  • [2] Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol 2. 4th edn. IARC Press, Lyon
  • [3] Sanchez JF (2011) Treatment of myelodysplastic syndromes in elderly patients. Adv Ther 28Suppl 2:1–9 [Crossref]
  • [4] Blum W (2010) How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2010:314–321 http://dx.doi.org/10.1182/asheducation-2010.1.314[Crossref][WoS]
  • [5] Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, Grossi F (2001) Fatigue: a main component of anaemia symptomatology. Semin Oncol 28(2 Suppl 8):15–18 http://dx.doi.org/10.1016/S0093-7754(01)90207-6[Crossref]
  • [6] Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA (2008) Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res 32(5):691–698 http://dx.doi.org/10.1016/j.leukres.2007.10.015[WoS][Crossref]
  • [7] Caocci G, La Nasa G, Efficace F (2009) Healthrelated quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol 2(1):69–80 http://dx.doi.org/10.1586/17474086.2.1.69[Crossref][WoS]
  • [8] Cella D (1998) Factors influencing quality of life in cancer patients: anaemia and fatigue. Semin Oncol 25(3 Suppl 7):43–46
  • [9] Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ (2003) Quality of life measurement in patients with transfusiondependent myelodysplastic syndromes. Br J Haematol 121(2):270–274 http://dx.doi.org/10.1046/j.1365-2141.2003.04272.x[Crossref]
  • [10] Pinchon DJ, Stanworth SJ, Doree C, Brunskill S, Norfolk DR (2009) Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol 84(10):671–677 http://dx.doi.org/10.1002/ajh.21503[Crossref][WoS]
  • [11] Thomas ML (1998) Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res 22 Suppl 1:S41–47 http://dx.doi.org/10.1016/S0145-2126(98)00055-1[Crossref]
  • [12] Oliva EN, D’Angelo A, Martino B, Nobile F, Dimitrov BD, Perna A (2002) More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 20(14):3182–3183; author reply 3183–3184
  • [13] Bowling A (2001) Measuring disease. A review of disease-specific quality of life measurement scales. Second edn. Open University Press, Buckingham, UK.
  • [14] Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometr 22:293–296
  • [15] George D, Mallery P (2003) SPSS for Windows step by step: A simple guide and reference, vol 11.0 update. 4th edn. Allyn & Bacon, Boston
  • [16] Terrell JE, Nanavati KA, Esclamado RM, Bishop JK, Bradford CR, Wolf GT (1997) Head and neck cancer-specific quality of life: instrument validation. Arch Otolaryngol Head Neck Surg 123(10):1125–1132 http://dx.doi.org/10.1001/archotol.1997.01900100101014[Crossref]
  • [17] Oliva EN, Dimitrov BD, D’Angelo A, Martino B, Perna A, Nobile F (2001) QOL-E: A new tool for the assessment of quality of life (QOL) in myelodysplastic syndrome (MDS). Proceedings of the 43rd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL; USA Blood 98:Abstract 427
  • [18] Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579
  • [19] Oliva EN, Dimitrov BD, Benedetto F, D’Angelo A, Nobile F (2005) Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 29(10):1217–1219 http://dx.doi.org/10.1016/j.leukres.2005.03.004[Crossref]
  • [20] Oliva EN, Nobile F, Alimena G, Specchia G, Danova M, Rovati B, Ronco F, Impera S, Risitano A, Alati C, Breccia M, Carmosino I, Vincelli I, Latagliata R (2010) Darbepoetin alfa for the treatment of anaemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 51(6):1007–1014 http://dx.doi.org/10.3109/10428191003728610[WoS][Crossref]
  • [21] Oliva EN, Latagliata R, Laganà C, Breccia M, Galimberti S, Morabito F, Poloni A, Balleari E, Cortelezzi A, Palumbo G, Sanpaolo G, Volpe A, Specchia G, Finelli C, D’Errigo MG, Rodà F, Alati C, Alimena G, Nobile F, Aloe Spiriti MA (2013) Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk Lymphoma (first online on 27 March 2013, doi:10.3109/10428194.2013.778406) [Crossref]
  • [22] Dimitrov BD, Serbezova D, Oliva EN, Nobile F (2003) Quality of life (QoL) in myelodysplastic syndrome in Bulgaria: a pilot survey. Leukemia Research 27(Supplement 1):S120–121
  • [23] Nilsson-Ehle H, Birgegard G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engstrom LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellstrom-Lindberg E (2011) Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of >/=120 g/L with darbepoetin alfa +/−filgrastim or erythrocyte transfusions. Eur J Haematol 87(3):244–252 http://dx.doi.org/10.1111/j.1600-0609.2011.01654.x[WoS]
  • [24] Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R (2006) Erythropoietin plus granulocyte colonystimulating factor is better than erythropoietin alone to treat anaemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 85(3):174–180 http://dx.doi.org/10.1007/s00277-005-0044-6[Crossref]
  • [25] Clavio M, Nobili F, Balleari E, Girtler N, Ballerini F, Vitali P, Rosati P, Venturino C, Varaldo R, Gobbi M, Ghio R, Rodriguez G (2004) Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur J Haematol 72(2):113–120 http://dx.doi.org/10.1046/j.0902-4441.2003.00183.x[Crossref]
  • [26] Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L (2008) Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142(3):379–393. doi:10.1111/j.1365-2141.2008.07181.x http://dx.doi.org/10.1111/j.1365-2141.2008.07181.x
  • [27] Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Oberg G, Porwit-MacDonald A, Radlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120(6):1037–1046 http://dx.doi.org/10.1046/j.1365-2141.2003.04153.x[Crossref]
  • [28] Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8):1794–1803. doi:10.1002/cncr.21792 http://dx.doi.org/10.1002/cncr.21792
  • [29] Kornblith AB, Herndon JE, 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20(10):2441–2452 http://dx.doi.org/10.1200/JCO.2002.04.044[Crossref]
  • [30] Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzara A, Pagnini D, D’Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC (2005) Impact of a new dosing regimen of epoetin alfa on quality of life and anaemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84(3):167–176 http://dx.doi.org/10.1007/s00277-004-0961-9[Crossref]
  • [31] Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S (2005) Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16(12):1921–1927 http://dx.doi.org/10.1093/annonc/mdi400[Crossref]
  • [32] Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Guglielmo P, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cavalieri E, Aloe Spiriti MA (2012) Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res 2(2):136–147
  • [33] Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, Breccia M, Vincelli I, Carmosino I, Guglielmo P, Pastore D, Alati C, Latagliata R (2011) Quality of life in elderly patients with acute myeloid leukaemia: patients may be more accurate than physicians. Haematologica 96(5):696–702 http://dx.doi.org/10.3324/haematol.2010.036715[Crossref]
  • [34] Von Mackensen S, Germing U, Gotze K, Giagounidis A, Oliva E (2011) Validation of a disease-specific quality of life questionnaire (QoL-E) for patients with myelodysplastic syndromes (MDS) in Germany. Leukemia Research 35:S63 http://dx.doi.org/10.1016/S0145-2126(11)70162-X[Crossref]
  • [35] Jurisic V, Colovic N, Terzic T, Djordjevic V, Colovic M (2012) Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukaemia: case report and review of literature. Pathol Res Pract 208(7):420–423 http://dx.doi.org/10.1016/j.prp.2012.04.007[WoS][Crossref]
  • [36] Oliva EN, D’Angelo A, Nobile F, Dimitrov BD, Perna A (2003) Quality of life in myelofibrosis with myeloid metaplasia: a cross-sectional study. Leuk Res 27(8):763–764 http://dx.doi.org/10.1016/S0145-2126(02)00326-0[Crossref]
  • [37] Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, Gäken J, Pennaneach C, Ireland R, Czepulkowski B, Pomplun S, Marsh JC, Mufti GJ (2013) TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 160(5):660–672 http://dx.doi.org/10.1111/bjh.12203
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-013-0196-z
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.